ClinicalTrials.gg

Program

sotiburafusp alfa

Also written as “HB0025 Injection”, “HB0025” and “HB0025 20 mg/kg plus nab-paclitaxel”.

Its studies are mostly in Endometrial Neoplasms · Carcinoma, Non-Small-Cell Lung · Kidney Neoplasms · Neoplasms, led by 2 companies.

Furthest: phase 3, since Jan 15, 20245 company-led studies, 4 open or runningNext primary completion: Jan 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Huabo Biopharm32 open or runningphase 2since Jan 15, 2024Dec 15, 2020Jan 15, 2027phase 2 · NCT07376629
Shanghai Huaota Biopharmaceutical22 open or runningphase 3since Jan 15, 2026Jan 15, 2026Apr 10, 2028phase 3 · NCT07383116

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2020First study: phase 1 study in NeoplasmsNew to Huabo BiopharmHuabo Biopharm · NCT04678908 · 154 enrolled · United States, China
  2. Jan 15, 2024Phase 2 study in Kidney NeoplasmsHuabo Biopharm · NCT06222125 · 100 planned · China
  3. Jan 13, 2026Phase 2 study in TNBCHuabo Biopharm · NCT07376629 · 60 planned · China
  4. Jan 15, 2026Shanghai Huaota Biopharmaceutical’s first study: phase 3 study in Non Squamous Non-small Cell Lung CancerNew to Shanghai Huaota BiopharmaceuticalShanghai Huaota Biopharmaceutical · NCT07383116 · 500 planned · China
  5. Oct 20, 2026Phase 3 study in First-line pMMR Endometrial CancerShanghai Huaota Biopharmaceutical · NCT07902999 · 333 planned · China

Ahead

  1. Jan 15, 2027Primary completion: phase 2 study in TNBCHuabo Biopharm · NCT07376629
  2. Apr 10, 2028Primary completion: phase 3 study in Non Squamous Non-small Cell Lung CancerShanghai Huaota Biopharmaceutical · NCT07383116
  3. Apr 23, 2029Primary completion: phase 3 study in First-line pMMR Endometrial CancerShanghai Huaota Biopharmaceutical · NCT07902999

TargetBeta

CD274 →read by rule
“A recombinant, humanized fusion protein composed of a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) ”NCIt, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
durvalumabruleAstraZenecaphase 4102
adebrelimabruleJiangsu HengRui Medicinephase 351
pumitamigBioNTechphase 334
benmelstobartruleSino Biopharmaceuticalphase 333
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 317
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
socazolimabruleLee's Pharmaceuticalphase 39
acasunlimabruleGenmabphase 36
fetrastobart vedotinPfizerphase 32
HLX37Fosun Pharmaphase 32

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07902999First-line pMMR Endometrial Cancer · China3RecruitingShanghai Huaota BiopharmaceuticalApr 23, 2029333
NCT07383116Non Squamous Non-small Cell Lung Cancer · China3Not yet recruitingShanghai Huaota BiopharmaceuticalApr 10, 2028500
NCT07376629TNBC · China2By invitationHuabo BiopharmJan 15, 202760
NCT06222125Kidney Neoplasms · China2RecruitingHuabo BiopharmJan 30, 2025100
NCT04678908Neoplasms · United States, China1UNKNOWNHuabo BiopharmFeb 2, 2024154

How it is read

Names in the registry

  • “HB0025 Injection”, 2 entries
  • “HB0025”, 2 entries
  • “HB0025 20 mg/kg plus nab-paclitaxel”, 1 entry
  • “HB0025 10 mg/kg plus nab-paclitaxel”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.